Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
Researchers have spent 40 years trying to find out how the chemical element sodium controls the signaling of opioid receptors in the brain - a class of receptors that play an important role in pain disorders and addictions. Now, scientists from The Scripps Research Institute and the University of North Carolina say they have finally uncovered the mechanism.
The research team, led by Dr. Gustavo Fenalti of The Scripps Research Institute (TSRI), says their findings could lead to the development of new drugs for an array of brain-related medical conditions.
Opioid receptors are naturally triggered by peptide neurotransmitters - endorphins, dynorphins and enkephalins - in the brain.
Synthetic and plant-derived drugs, such as morphine, codeine, oxycodone and heroin, can also activate opioid receptors by mimicking peptide neurotransmitters.
In the early 1970s, researchers from Johns Hopkins University discovered that sodium ions act as a switch for the signaling of opioid receptors, and furthermore, the ions can reduce the interaction between opioid peptides and mimicking drugs, and opioid receptors.
However, it has been unclear as to how sodium ions actually do this.
According to the investigators, opioid receptors have been difficult to study. They note that they are "flimsy and fragile" when created in isolation, meaning they are tricky to analyze using the standard "structure-mapping method" for large proteins - known as X-ray crystallography.
But for this study, findings of which have recently been published in the journal Nature, the team created a new "fusion-protein-stabilized" version of a major opioid receptor in the human brain - the delta opioid receptor.
They formed crystals of the new receptor, and using X-ray crystallography, the researchers were able to view its structure at a resolution of 1.8 angstroms, or 180 trillionths of a meter. The investigators note that this is the clearest picture to date of an opioid receptor.
From this, the researchers discovered that the delta opioid receptor has an "allosteric sodium site," in which a sodium ion can enter and change receptor activity.
They also detected amino acids that are responsible for triggering the signal-modulating activity of the sodium ions and keeping the ions in place.
"We found that the presence of the sodium ion holds the receptor protein in a shape that gives it a different affinity for its corresponding neurotransmitter peptides," explains Dr. Fenalti.
Commenting on their findings, Prof. Raymond Stevens, of TSRI and senior author of the study, says:
"This discovery has helped us decipher a 40-year-old mystery about sodium's control of opioid receptors. It is amazing how sodium sits right in the middle of the receptor as a co-factor or allosteric modulator."
The investigators then created new adaptations of the delta opioid receptor by mutating amino acids in the main sodium sites.
From this, the investigators found that changes in specific amino acids trigger major adjustments in the normal signaling response of the delta opioid receptor.
The researchers say these findings mean there may be many ways in which drugs could target not only delta opioid receptors, but also the other two opioid receptors in the brain, called mu and kappa.
"The sodium site architecture and the way it works seems essentially the same for all three of these opioid receptor types," says Dr. Fenalti.
Overall, the team says their research could lead to new treatment options for medical conditions related to the brain.
"It opens the door to understanding opioid related drugs for treating pain and mood disorders, among others," Dr. Fenalti adds.
In other news related to brain health, Medical News Today recently reported on a study suggesting that brain training boosts mental skills of older adults, while another study suggests caffeine may boost long-term memory.
Written by Honor Whiteman
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
Molecular control of δ-opioid receptor signalling, doi:10.1038/nature12944, Gustavo Fenalti, Patrick M. Giguere, Vsevolod Katritch, Xi-Ping Huang, Aaron A. Thompson, Vadim Cherezov, Bryan L. Roth, Raymond C. Stevens, published in Nature, 12 January 2014. Abstract
Scientists Solve 40-year Mystery of How Sodium Controls Opioid Brain Signaling, news release from The Scripps Research Institute, accessed 14 January 2014.
Visit our Neurology / Neuroscience category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Whiteman, Honor. "Scientists discover how sodium controls opioid receptor signaling." Medical News Today. MediLexicon, Intl., 14 Jan. 2014. Web.
17 Apr. 2014. <http://www.medicalnewstoday.com/articles/271208>
Whiteman, H. (2014, January 14). "Scientists discover how sodium controls opioid receptor signaling." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/271208.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.